

First author	No. of cases with available FU data	Overall recurrence	Benign Recurrence	Malignant recurrence	Local Recurrence	Distant Recurrence	Time to recurrence months, (range)	FU Duration months (range)
Boddeart^^	75	3/75 (4%)	0 (0%)	3/28 (10.7%)	3/75 (4%)	0%	19 <sup>(MD)</sup> (8-59)	69 <sup>(MD)</sup> (1-315)
Bylicki^^	68	26/68 (38%)	-	-	14/68 (20.6%)	12/68 (17.6%)	-	Unclear
Cardillo^	110	8/110 (7%)	4/95 (4%)	4/15 (27%)	-	-	-	(12-222)
Chu	29	0/29 (0%)	-	-	-	-	-	35 <sup>(MN)</sup> (2-117) 65.5 <sup>(MD)</sup>
Demicco (2012)		12/29 (41.4%)	-	-	3/29 (10%)	9/29 (31%)	Local: 141 <sup>(MD)</sup> (15-195) Metastases: 30 <sup>(MD)</sup> (4-119)	48 <sup>(MD)</sup> (0-279)
Demicco (2017)	20	1/20 (5%)	-	-	0/20 (0%)	1/20 (5%)	-	Mixed data
DeVito^	28	12/28 (42.9%)	4/15 (27%)	8/13 (61.5%)	6/28 (21.4%)	8/28 (28.6%)	-	55.3 <sup>(MD)</sup>
England	169	28/169 (16.6%)	2/98 (2%)	39/71 (55%)	-	-	-	57 <sup>(MD)</sup>
Enon	25	0/25 (0%)	-	-	-	-	-	33.6 <sup>(MN)</sup> (9-142)
Franzen	42	4/42 (9.5%)	-	-	-	-	-	39 <sup>(MD)</sup> (14-78)
Gholami		-	-	-	7/66 (10.6%)	7/67 (10.4%)	-	73 <sup>(MN)</sup> (1-264)
Guo^^	38	1/38 (2.6%)	0/35 (0%)	1/4 (25%)	0/39 (0%)	1/39 (2.6%)	6 <sup>(MD)</sup>	40.3 <sup>(MN)</sup> (30-89)
Gupta	16	3/16 (18.8%)	0/10 (0%)	3/6 (50%)	3/16 (18.8%)	0/16 (0%)	-	36 <sup>(MN)</sup> (12-120)
Harrison-Phipps^^	84	8/84 (9.5%)	2/73 (2.7%)	6/11 (54.5%)	3/81 (3.7%)	5/81 (6.2%)	mSFTP – 34 <sup>(MD)</sup> bSFTP – 83 <sup>(MD)</sup>	146 <sup>(MD)</sup> (23-387)
Helage	9	7/9* (77.8%)	0	7*	7*	0*	36 <sup>(MD)</sup>	27 <sup>(MD)</sup> (3-84)

							(2 – 84)	
Kim	40	5/40 (12.5%)	-	-	4/40 (10%)	1/40 (2.5%)	4 years	Mixed data
Lahon <sup>^</sup>	102	15/102 (14.7%)	2/60 (%)	13/42 (%)	10/102 (%)	5/102 (%)	29 <sup>(MD)</sup>	168 <sup>(MD)</sup>
Liu	21	0/21 (0%)	0/21 (0%)	0/21 (0%)	0/21 (0%)	0/21 (0%)	-	43 <sup>(MD)</sup>
McGuire <sup>^</sup>	23	4/23 (17.4%)	3/15 (20%)	1/8 (12.5%)	3/23 (13%)	1/23 (4.3%)	Local: 176 <sup>(MN)</sup> ±82 Metastases: 87 <sup>(MN)</sup> ±4	125.8 <sup>(MN)</sup>
O'Neil		-	-	-	-	12/57 (21%)	-	39.6/41.8 <sup>(MN)</sup> in select groups
Rena <sup>^</sup>	21	1/21 (5%)	0/13 (0%)	1/8 (12.5%)	1/21 (5%)	0/21 (0%)	124 <sup>(MD)</sup>	68 <sup>(MD)</sup> (2-189)
Santos <sup>^</sup>	34	6/34 (17.6%)	0/27 (0%)	6/7 (85.7%)	6/34 (17.6%)	0/34 (0%)	9 <sup>(MN)</sup>	34 <sup>(MD)</sup>
Schmid	22	3/22 (13.6%)	1/16 (6.3%)	2/6 (33%)	1/22 (4.5%)	2/22 (9.1%)	40 <sup>(MD)</sup> (14 – 42)	28 <sup>(MD)</sup> (1-160)
Tan <sup>^^</sup>	81	4/81 (4.9%)	0/70 (0%)	4/11 (36.4%)	4/81 (4.9%)	0/81 (0%)	-	56 <sup>(MD)</sup>
Tapias	59	8/59 (14%)	3**	5**	8/59 (14%)	0/59 (0%)	6 years <sup>(MD)</sup> (2-16)	104 <sup>(MN)</sup>
Vejvodova <sup>^^</sup>	22	2/22 (9.1%)	0/22 (0%)	2/22 (9.1%)	2/22 (9.1%)	0/22 (0%)	-	45 <sup>(MD)</sup> (1-188)
Yeom	41	5/41 (12.2%)	0/35 (0%)	5/6 (83.3%)	2/41 (4.9%)	3/41 (7.3%)	-	Unclear

\* Personal communication with the authors suggested that the follow up was biased towards patients who represented with recurrence

\*\* Denominator unclear

<sup>^</sup> Patients with information available for number reresections for recurrence

<sup>^^</sup> Patients with information regarding repeated recurrence after re-resection